Dong-A ST Co., Ltd.

The GEROPHARM Group has concluded a licensing agreement with South Korea’s Dong-A ST for the exclusive development and promotion of a new drug to treat Type 2 Diabetes.

“We are interested in developing a portfolio of drugs to treat diabetes since this is one of the priorities for our development,” Peter Rodionov commented. “Based on the agreement with our Korean partner, we will handle the development of the finished dosage form and the registration of the new drug in Russia, Kazakhstan and Ukraine, and we are planning to put it on the market in 2017.”

20 July 2015

Investor profile

Dong-A ST Co., Ltd.

South Korea

Company's website:

T: 82-02-920-8114

Public company

Contact: Kim Won-bae, CEO

Dong-A ST Co., Ltd. manufactures pharmaceutical products, including vaccines, AIDS diagnosis devices, chemotherapy, nutritional and health drinks as well as antipyretic, analgesic and other patented drugs.